Indian pharma: Unethical practices, marketing rules under lens; new review body set up
Reported by Economic Times Industry, not nibnow. We are not the publisher of this story, only the source is.
The review of pharmaceutical marketing practices could influence how drug companies interact with doctors and affect the availability and cost of medicines for patients.
The review comes against the backdrop of the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), which was introduced in 2015 as a voluntary, industry-led mechanism to promote ethical conduct in pharmaceutical marketing and regulate interactions between drug companies and healthcare professionals.
The Uniform Code for Pharmaceutical Marketing Practices, introduced in 2015, is a voluntary, industry‑led set of guidelines intended to ensure ethical marketing and regulate contacts between drug makers and healthcare professionals.
- •Announcements about the mandate and powers of the new review body
- •Potential revisions to the UCPMP guidelines
- •Reactions from pharmaceutical companies and medical associations